Johnson & Johnson - Jun 29, 2021 Form 3 Insider Report for CVRx, Inc. (CVRX)

Role
10%+ Owner
Signature
Johnson & Johnson By: /s/ Matthew Orlando, Secretary
Stock symbol
CVRX
Transactions as of
Jun 29, 2021
Transactions value $
$0
Form type
3
Date filed
6/29/2021, 09:45 PM
Next filing
Jul 2, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVRX Series D-2 Preferred Stock Jun 29, 2021 Common Stock 102K See footnote F1, F2, F3
holding CVRX Series E-2 Preferred Stock Jun 29, 2021 Common Stock 163K See footnote F1, F2, F3
holding CVRX Series F-2 Preferred Stock Jun 29, 2021 Common Stock 192K See footnote F1, F2, F3
holding CVRX Series G Preferred Stock Jun 29, 2021 Common Stock 3.04M See footnote F1, F3, F4
holding CVRX Warrant to Purchase Series G Preferred Stock Jun 29, 2021 Common Stock 608K $0.40 See footnote F5, F6
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 237 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 158 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 189 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 165 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 118 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 71 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 23 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 85 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 758 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 489 $0.24 See footnote F3, F7
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 758 $0.24 See footnote F3, F8
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 300 $0.24 See footnote F3, F8
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 758 $1.19 See footnote F3, F9
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 142 $1.19 See footnote F3, F9
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 758 $3.96 See footnote F3, F10
holding CVRX Stock Option (Right to Buy) Jun 29, 2021 Common Stock 1.26K $5.14 See footnote F3, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of preferred stock is convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion ratio for no additional consideration and has no expiration date. The shares of preferred stock will automatically convert into shares of Common Stock at the then-applicable conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares) upon the closing of the Issuer's initial public offering. The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.
F2 Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock are convertible into shares of Common Stock at a rate of 1-for-0.025857287.
F3 These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
F4 Shares of Series G Preferred Stock are convertible into shares of Common Stock at a rate of 1-for-0.0632143218.
F5 The Warrant to Purchase Series G Preferred Shares shall become exercisable for Common Stock upon the closing of the Issuer's initial public offering and expires on the earlier of (i) an acquisition or asset transfer involving the Issuer or (ii) 180 days after receipt of the data from a certain clinical trial.
F6 These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Biosense Webster, Inc., an affiliate of Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
F7 Fully vested.
F8 Vests as to 1/48th of the shares each month commencing March 16, 2018.
F9 Vests as to 1/48th of the shares each month commencing December 29, 2018.
F10 Vests as to 1/48th of the shares each month commencing January 6, 2020.
F11 Vests as to 1/48th of the shares each month commencing January 11, 2021.